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Azeri Turkish populationRett syndrome is a dominant X-linked male-lethal disorder largely caused by mutations in the gene encoding
methyl-CpG binding protein 2 (MECP2). Clinicalmanifestations include neurodevelopmental disorder character-
ized by early-onset intractable seizures, severe developmental delay, intellectual disability, and abnormal elec-
troencephalograms. Afﬂicted females show normal development until the age of 6 to 18 months, followed by
gradual loss of speech abilities, microcephaly, social impairment, ataxia, and stereotypic hand movements. We
report a 7-year-old girl who was born of a nonconsanguineous marriage presenting with mental retardation
and delayed development. Physical examination revealed loss of speech, repetitive hand-wringing movement,
short stature (120 cm), strabismus, microcephaly, and autistic behavior. The diagnosis was conﬁrmed by se-
quencing MECP2 gene with heterozygous mutation C385A in exon 2. The current study aimed to report the
ﬁrst case of Rett syndrome in the Azeri Turkish population.
© 2014 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Rett syndrome (RTT) is a childhood neurodevelopmental disorder,
with an approximate prevalence of 1 in 10,000–15,000 female live
births. The syndrome is characterized by normal early development,
followed by loss of purposeful use of hands, distinctive hand move-
ments, slowed growth of brain and head, gait abnormalities, seizures,
and mental retardation [1–3]. Infants with RTT show normal growth
and development until the age of 6–18months, followed by backsliding
of development and regression of skills and abilities; they often exhibit
autistic behaviors in the early stages. Other likely symptoms include toe
walking; sleep problems; wide-based gait; teeth grinding and difﬁculty
chewing; slowed growth; seizures; cognitive disabilities; and breathing
problems when awake, such as hyperventilation, apnea, and
swallowing air [1,2]. Rett syndrome is a dominant X-linked disorder
and a common genetic cause of mental retardation in girls. In males,
however, the mutation usually results in severe clinical manifestations
and leads to lethality in the male fetus [4].
The discovery of the gene responsible for RTT (GenBank Accession
No.: AF030876.2, OMIM: 300005) has permitted studies on the distribu-
tion of various mutations in different geographic and ethnic groups [5].98 41 33373741.
en access article under the CC BY-NCRett syndrome is caused by mutations in the MECP2 gene, which has
been mapped to the locus Xq28. The MECP2 gene encodes the protein
methyl-CpG binding protein 2 (MECP2), which functions as one of
several biochemical switches; patients with RTT show improper
functioning of this gene and insufﬁcient amounts or structurally
abnormal forms of the protein [1,2]. Methyl-CpG binding protein 2
functions as a transcriptional repressor, an activator, and an RNA-
binding protein. Systematic studies of the MECP2 gene revealed a
range of mutations which were associated with different phenotypes
[6]. In vivo studies usingmice withMECP2mutations revealed neuro-
pathological and behavioral deﬁcits similar to those reported for
RTT [7–9].
Mutations in the MECP2 gene were observed in 70%–80% of the
girls diagnosed with RTT using current diagnostic techniques. The re-
maining 20%–30% of the cases were attributed to partial gene deletion
and unknown mutations [1,2].
Mutations in CDKL5 (cyclin-dependent kinase-like 5) gene are
associated with clinical manifestations in a few patients with RTT
[10]. CDKL5 has been mapped to the locus Xp22.3; different muta-
tions in the gene have been detected in girls (heterozygous mutations)
and a few boys, with all subjects presenting early-onset intractable
seizures [11,12]. Recently, a novel mutation has been identiﬁed
(p.z D263VfsX190) in FOXG1 gene in a patient with a congenital variant
of RTT, which results in an altered reading frame of the entire coding
sequence downstream of the mutation [13].-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2.1. History and examination
A 7-year-old girl (Fig. 1), an only child who was born of a
nonconsanguineous marriage and through vaginal delivery, was
brought to ourMedical Genetic Centre inMarch 2014 because ofmental
retardation. At birth, her father andmotherwere 25 and 23 years of age,
respectively. Normal development was observed until the age of 6
months, following which development regressed. Loss of eye contact
was observed at the age of 7 months, followed by a gradual change
into an introvert. The patient had been previously examined by several
doctors, and a diagnosis of autism had been made based on behavior.
Finally, because of lack of improvement in symptoms, the patient was
referred to our Medical Centre.
Clinical examination carried out at the time of initial presentation
revealed microcephaly (HC = 49 cm), short stature (120 cm), low-set
ears, strabismus, repetitive hand wrestling movement, irritability,
sleep disturbances, loss of speech, and autistic behavior. Normal
HC was observed at birth, followed by slowing of the rate of head
growth from the age of 6months. This symptomproﬁle led to initial sus-
picions of inborn errors of metabolism; therefore, chromatography of
serum amino acids was carried out, which revealed nonspeciﬁc
changes.2.2. Paraclinical ﬁndings
Brain CT scan was normal. The clinical and paraclinical ﬁndings
prompted suspicions of RTT, and a molecular genetic test was carried
out. The blood sample was sent to the Laboratory of Houshmand in
Tehran, Iran. Polymerase chain reaction (PCR) and bidirectional se-
quencing of theMECP2 gene revealed a heterozygous mutation C385A
(Ala to Asp) in exon 2, indicating positivity for RTT.
After several years, her parents decided to get pregnant again. They
were referred to the gynecologist with records of their daughter. DuringFig. 1. Affected child at 18 months of age.pregnancy, amniocentesis and DNA testingwere reported to be normal,
and ﬁnally, a healthy male child was born.
Coincidentally, during the time we evaluated this family, we were
studying the genetic aspects of other genetic diseases [14–16].
2.3. Follow-up and representation
At her last visit, the patient was 15 years old (Figs. 2–4), and clinical
examination revealed microcephaly (HC = 52 cm), short stature
(145 cm), sleep disturbances, repetitive hand wrestling movement,
rigidity ofmuscle hands, curved legs, irritability, loss of speech andwrit-
ing and reading, sleep disturbances, strange noises, and lack of control
over urinary and fecal excretion. Their son was a healthy child
(Figs. 2–4).
3. Discussion
3.1. Clinical prognosis
Rett syndromewas originally described by Dr. Andres Rett of Austria
in 1966 and was globally recognized two decades later following the
publication of a report that described 35 affected girls from Sweden,
Portugal, and France [17,18]. Rett syndrome is considered the second
common cause of mental retardation in females after Down syndrome
[19]. Four stages are typically associated with RTT. Stage I, called early
onset, generally begins between the ages of 6 and 18 months. This
stage is frequently overlooked because the subtle symptoms of slowing
development are likely to be somewhat vague and quite possibly
missed by parents and specialists. There is reduced eye contact and less-
er interest in toys and, possibly, delays in gross motor skills. This stage
usually lasts for a few months but can persist for more than a year.
Stage II, or the rapid destructive stage, usually begins between the
ages of 1 and 4 years. This stage could have either a rapid or a gradual
onset as purposeful hand skills and spoken language are lost. Hands
are sometimes clasped behind the back or held at the sides. These
movements persist while the child is awake but disappear during
sleep. Autistic behaviors such as loss of social interaction and communi-
cation could also be encountered. Breathing irregularities, general irrita-
bility, slowing of head growth, and sleep irregularities are likely to beFig. 2. Affected child at 15 years of age.
Fig. 3. Hand wrestling.
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motor movements. Stage III, also called the plateau or the
pseudostationary stage, usually begins between the ages of 2 and 10Fig. 4. The patient in standing position.years. Apraxia, motor problems, and seizures are prominent during
this stage. However, improvement in behavior (lesser irritability and
crying), alertness, attention span, and communication skills is likely.
Several affected females remain in this stage for the greater part of
their lives. The last stage, stage IV or the late motor deterioration
stage, is characterized by reduced mobility, muscle weakness, rigidity
(stiffness), spasticity, and increased dystonia. In general, decline in
cognition, communication, or hand skills is not observed in stage IV.
Feeding disorders and poor weight gain are common. The clinical
criteria required for a diagnosis of RTT are of three kinds: essential, sup-
portive, and exclusion. Essential diagnostic criteria or symptoms include
(1) normal HC at birth followed by slowing of the rate of increase in HC
between 6 and 18 months of age and apparently normal development
until 6–18months of age, followed by (2) normal HC at birth or slowing
of the rate of head growth between 3 months and 4 years of age, with
either followed by impaired expressive language; repetitive hand
movements; shaking of the torso; and toe-walking or unsteady, wide-
based, and stiff-legged gait. Supportive criteria are not required for a di-
agnosis of RTT; a child with supportive criteria but none of the essential
criteria is not diagnosed with RTT. Supportive criteria include breathing
difﬁculties; electroencephalogram (EEG) abnormalities; seizures; mus-
cle rigidity, spasticity, and/or joint contracture; scoliosis; teeth-
grinding; small feet in relation to height; growth retardation; decreased
body fat and muscle mass; abnormal sleep pattern; irritability or agita-
tion; chewing and/or swallowing difﬁculty; poor circulation in the
lower extremitieswith cold and bluish-red feet and legs; decreasedmo-
bility with age; and constipation. Children with any of the following ex-
clusion criteria do not receive a diagnosis of RTT: enlargement of body
organs or other signs of storage disease, vision loss due to retinal disor-
der or optic atrophy, microcephaly at birth, an identiﬁable metabolic
disorder or other inherited degenerative disorders, an acquired neuro-
logical disorder, and evidence of in utero growth retardation or of
brain damage acquired after birth [1,2,6]. Rett syndrome is most often
misdiagnosed as autism, cerebral palsy, or nonspeciﬁc developmental
delay. Differential diagnosis varies by clinical stage [20], and the list is
presented in Table 1 as per the clinical stage.
3.2. Candidate genes
Rett syndrome is caused by mutations (structural alterations or
defects) in the MECP2 gene located on the X chromosome and has
been detected in 70%–80% of girls diagnosed with RTT. Methyl-CpG
binding protein 2 has been mapped to the chromosome Xq28 between
the loci IRAK (interleukin-1 receptor-associated kinase) and RCP (red
posing gene) [21]. TheMECP2 gene spans approximately 76 kb and en-
codesMECP2 of 487 amino acids. Given that the disorder occurs sponta-
neously in most individuals with MECP2 mutation, the incidence of
asymptomatic carriers of the disorder is an extremely rare possibility.
Certain caseswith atypical RTT did not carry any of the reportedmu-
tations inMECP2. Mutation in the CDKL5 gene was found to result in an
atypical form of RTT in females, called ‘early-onset seizure’ [10]. Of the
two X chromosomes in females, only one is active in any given cell.
Therefore, in a child with RTT, nearly 50% of the cells in the nervous
system show expression of the defective gene, while the rest show
expression of the wild type gene and normal amounts of the protein.
In males with MECP2 mutation, however, the situation is different:
males have a single copy of the X chromosome and, therefore, lack a
wild type copy of the gene that could potentially compensate for the de-
fective one, resulting in lethality. Differentmutations in theMECP2 gene
have been detected in affected males with mental retardation [1,2,19,
22], and recent reports have revealed that mild phenotypes are caused
by deletions in the locus Xq28 [23].
Thiery Bienvenu et al. reported a total of 30 mutations in MECP2
among 46 girls with typical RTT; these include 12 novel mutations,
5 of which were nonsense mutations [R168X (n= 3), R198X (n= 1),
R255X (n = 2), R270X (n = 5), and R294X (n = 3)], 3 were
Table 1
The list of differential diagnosis with Rett syndrome.
Stage I
Developmental arrest (typically
in children 6–18 months of age)
Stage II
Rapid deterioration or regression
(typically in children 1–4 years of age)
Stage III
Pseudostationary (typically
in children 2–10 years of age)
Stage IV
Late motor deterioration
(typically in patients N10 years)
Benign congenital hypotonia Autism Spastic ataxia Other degenerative disorders
Cerebral palsy Angelman syndrome Cerebral palsy
Prader–Willi syndrome Encephalitis Spinocerebellar
Metabolic disorders (e.g., fetal
alcohol syndrome, trisomy 13)
Hearing and/or visual disturbance degeneration
Landau–Kleffner syndrome Leukodystrophies
Psychoses Neuroaxonal dystrophy
Slow virus Lennox–Gastaut syndrome
Panencephalopathy Angelman syndrome (likely
not Kabuki because patients
would have macrocephaly)
Tuberous sclerosis
Metabolic disorders (e.g., phenylketonuria,
ornithine transcarbamylase deﬁciency)
Infantile neuronal ceroid lipofuscinosis
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1)], 1 insertion [677insA (n = 1)], 4 deletions [1156del17 (n = 1),
1158del10 (n = 1), 1163del26 (n = 1), and 1164del26 + 1165A→T
(n= 1)], and 1 silent polymorphism (S194S). The nonsense mutations
weremost frequently (4 of 5 cases) due to C→T transitions occurring in
CpG dinucleotides [3].
The study by Wan et al. reported multiple recurrences of nonsense
(R168X, R255X) and missense (R106W, R306C) mutations in MECP2.
R168X mutation was observed in 6 unrelated sporadic cases, including
2 affected sisters and their healthy mother. The missense mutations pre-
served the domain structure ofMECP2. All the mutations involved C→T
transitions at CpG hotspots. Moreover, a single nucleotide deletion was
recognized at codon 137, resulting in L138X mutation within the
methyl-binding domain. A deletion (806delG) that resulted in the muta-
tion V288X in the transcription–repression domainwas identiﬁed in a fe-
male patientwithX inactivation aswell as in her sister and daughter,who
were afﬂicted with classic RTT, and her homozygous son, who died from
congenital encephalopathy [24]. Huppke et al. in Germany identiﬁed the
mutations T158M, R168X, R255X, and R270X in 24 females [25]. Meloni
et al. in Italy identiﬁed Xq27.2-qter in 2male patients presentingwith se-
vere mental retardation and progressive spasticity, and 2 obligate carrier
females were found to simulate an X-linked recessive trait [26].4. Management
There are currently no known speciﬁc treatments for RTT. Clinical
care, therefore, comprises genetic counseling (with DNA tests to
rule out familial transmission), support and advice for the families,
anticonvulsant medication upon the development of epilepsy, and
physiotherapeutic measures for alleviating scoliosis development to
the extent possible.
During regression, certain features of RTT are similar to those of au-
tism; misdiagnosis of RTT as autism is, therefore, likely. The important
role played by genetic factors in these conditions should be considered
by individuals concerned with autism spectrum disorders, including
psychiatrists, psychologists, or pediatricians. Of note, the current study
features the ﬁrst report of a mutation in RTT among the Azeri Turkish
population of Iran.Ethical standards
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